BIO-TECHNE Corp vs Welltower Inc. Common Stock — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Welltower Inc. Common Stock trades at $223.12 (market cap $159.33B). The key difference: Welltower Inc. Common Stock is far larger — about 14× BIO-TECHNE Corp's market cap, and Welltower Inc. Common Stock pays the higher dividend (1.54%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Welltower Inc. Common Stock for 0 Days on average.
| TECH | WELL | |
|---|---|---|
Market Cap | $11.36B | $159.33B |
Volume | 5,390,331 | 2,484,986 |
Sector | Health | Real Estate |
52-Week High | $72.61 | $252.07 |
52-Week Low | $43.31 | $165.94 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $11.39B | $177.09B |
Dividend Yield | 0.44% | 1.54% |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Welltower is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, outpatient medical facilities, and other health-related real estate.
Read more on WELL →